

DAFTAR PUSTAKA

- Armstrong EP and Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. *Clin Ther*, 2003; 25: 1-18.
- Birrell F, Howells N, and Porcheret M. Osteoarthritis: Pathogenesis and Prospects for Treatment. *Reports on the Rheumatic Diseases (Series 6)*, 2011. www.arthritisresearchuk.org/medical-professional-info, diakses pada tanggal 17 Desember 2015 pukul 21.03.
- Budiarto E. 2004. *Metodologi Penelitian Kedokteran*. Penerbit Buku Kedokteran EGC. Jakarta.
- Botting RM. Inhibitors of cyclooxygenases: mechanisms, selectivity and uses, *The William Harvey Research Institute*. 2006. www.jpp.krakow.pl/journal/archive/11_06_s5/pdf/113_11_06_s5_article.htm]. Diakses pada tanggal 1 Agustus 2016 pukul 0.13.
- Chan KKW and Wu RWK. Symptoms, Signs and Quality of Life (QoL) in Osteoarthritis (OA). *Principles of Osteoarthritis- Its Definition, Character, Derivation and Modality-Related Recognition*, 2012; 25-40. <http://www.intechopen.com/books/principles-of-osteoarthritis-its-definition-character-derivation-and-modalityrelated-recognition/symptoms-signs-and-quality-of-life-qol-in-osteoarthritis-oa>, diakses pada tanggal 17 Desember 2015 pukul 20.37.
- Crofford LJ. Use of NSAIDs in treating patients with arthritis. *Arthritis Research & Therapy*, 2013; (15) Suppl 3: S2.
- Digler K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U. Effects of Celecoxib and Diclofenac on Blood Pressure, Renal Function, and Vasoactive Prostanoids in Young and Elderly Subjects. *The Journal of Clinical Pharmacology*. 2002; 42: 985-994
- Dipiro, JT, Robert L. T, Gary C Y, Gary R.M, Barbara G. W, L. Michael P. 2008. *Pharmacotherapy: A Pathophysiologic Approach, seventh edition*. Mc Graw Hill. New York.
- Felson DT. Osteoarthritis of the knee. *The new england journal of medicine*. 2006. (354): 841-848.
- Grover SA, Coupal L, and Zowall H. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure stabilization? *Hypertension*, 2005; 45(1):92-97.
- Handono, K. 2012. *Hubungan Kadar C-Terminal Telopeptide Kolagen Tipe-II (CTX-II) Urin Dengan Derajat Kerusakan Sendi Pada Pasien Osteoarthritis Lutut*. Tugas Akhir. Tidak diterbitkan. Fakultas Kedokteran Universitas Brawijaya. Malang.

- Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, *et al.* Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *American College of Rheumatology*, 2012; 64 (4): 465-474.
- IRA^a. 2014. *Diagnosis dan Penatalaksanaan Osteoarthritis*. Perhimpunan Reumatologi Indonesia. Jakarta.
- IRA^b. 2014. *Penggunaan Obat Anti Inflamasi Non Steroid*. Perhimpunan Reumatologi Indonesia. Jakarta.
- Kozier B, Erb GL, Berman A, Snyder SJ, Levett-Jones T, Dwyer T *et al.* 2015. *Fundamentals of Nursing*. National Library of Australia. Melbourne.
- Laar M, Joseph VP, Pergolizzi Jr, Hans-Ulrich M, Ignacio MM, Srivinas N, Joanne O, Serge P, and Robert BR. Pain treatment in arthritis-related pain: beyond NSAIDs. *The Open Rheumatology Journal*, 2012 (6): 320-330.
- Michael JW, Schlüter-Brust KU, and Eysel P. The Epidemiology, Etiology, Diagnosis, and Treatment of Osteoarthritis of the Knee. *Deutsches Ärzteblatt International*, 2010; 107(9): 152–62.
- Muttaqin A. 2009. *Asuhan Keperawatan Klien dengan Gangguan Sistem Kardiovaskular dan Hematologi Edisi Pertama*. Salemba Medika, Jakarta.
- NCC-CC (The National Collaborating Centre for Chronic Conditions). 2008. Osteoarthritis. *National Clinical Guideline for Care and Management in Adults*. Royal College of Physicians. London.
- Neal D. 2005. *At a Glance Farmakologi Medis Edisi Kelima*. Erlangga Medical Series. Jakarta.
- Pal GK and Pal P. 2005. *Textbook of Prectical Physiology*. Colour Impression Ltd. Chennai.
- Poole AR, Kobayashi M, Ysuda T, Laverty S, Mwale F, Kojima T, Sakai T, Wahl C, El-Maadawy S, Webb G, Tchetina E, Wu W. Molecular mechanisms of cartilage and bone destruction: Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. *Ann Rheum Dis* 2002; 61:ii78-ii81.
- Rafey, MA. 2013. Hypertension. *The Cleveland Clinic Foundation*. <http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/arterial-hypertension/>, diakses pada tanggal 12 Agustus 2016 pukul 21.50.
- Rao PNP and Knaus EE. Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond. *Pharm Pharmaceut Sci*, 2008;11 (2): 81-110.
- Scott DL, Berry H, Capell H, Coppock J, Daymond T, Doyle DV, *et al.*. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of

- knee: a randomised placebo-controlled trial. *Rheumatology*, 2000; (39): 1095-1101.
- Snowden S and Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. *Cardiol Rev*. 2011; 19(4):184-91.
- Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. *Arch Intern Med*. 2005 Jan 24;165(2):161-8.
- Stolfi C, Simone VD, Pallone F, and Monteleone G. Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer. *International Journal of Molecular Sciences*, 2013; 14: 17972-17985.
- Sweetman SC. 2009. *Martindale The Complete Drug Reference: Thirty –Sixth Edition*. Pharmaceutical Press. London.
- Villa-Forte, A. *Effects of Aging on the Musculoskeletal System*. 2016. <https://www.merckmanuals.com/home/bone,-joint,-and-muscle-disorders/biology-of-the-musculoskeletal-system/effects-of-aging-on-the-musculoskeletal-system>. Diakses pada tanggal 30 Agustus 2016 pukul 10.18.
- Waranugraha Y, Suryana BPP, Pratomo B. Hubungan Pola Penggunaan OAINS dengan Gejala Klinis Gastropati pada Pasien Reumatik. *Jurnal Kedokteran Universitas Brawijaya*, 2010; 26 (2): 107-112.
- Warner TD and Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. *Lancet* , 2008; 371 (9608):270-3.
- Watson MC, Brookes ST, Kirwan JR, and Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. (Abstract). *Cochrane Database Syst Rev*, 2000; (2):CD000142.
- Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. *Am J Ther*, 2000; (7): 63-74.
- White WB. Cardiovascular effects of the cyclooxygenase inhibitors. *Hypertension*, 2007; (49): 408-418.
- Zanchetti A, Hansson L, Dahlof BR. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk. *J Hypertens*, 2002; (20): 2301–2307.
- Zhang Y and Jordan JM. Epidemiology of osteoarthritis. *Clin Geriatr Med*. 2010; (3): 355–369.